Annaliese Noack, DO
Internal Medicine · Williamsville, NYNPI 1750510418
Payments from drug & device makers
Across 162 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$293
- AbbVie$282
- AstraZeneca$251
- Boehringer Ingelheim$210
- Johnson & Johnson$143
- GSK$119
- plus $1K from 20 others
What the payments were for
- Food & beverage$2,29999%
- Education$131%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 29 | $293 |
| AbbVie(2 entities) | 19 | $282 |
| AstraZeneca | 13 | $251 |
| Boehringer Ingelheim | 14 | $210 |
| Johnson & Johnson | 12 | $143 |
| GSK | 9 | $119 |
| Merck | 7 | $108 |
| Amarin Pharma, Inc. | 5 | $94 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $89 |
| Astellas Pharma US Inc | 5 | $84 |
| Novartis | 4 | $79 |
| Amgen | 5 | $75 |
| Eisai Inc. | 5 | $73 |
| Pfizer | 5 | $72 |
| Lilly USA, LLC | 5 | $69 |
| Exact Sciences | 3 | $59 |
| Sanofi-aventis U.S. LLC | 2 | $39 |
| Grifols USA, LLC | 2 | $37 |
| Upsher-smith Laboratories LLC | 2 | $37 |
| Medtronic | 1 | $18 |
| Radius Health, Inc. | 1 | $17 |
| Collegium Pharmaceutical, Inc. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
| Otsuka America Pharmaceutical, Inc. | 1 | $11 |
How this compares
$2,312 in reported general payments places this provider in the 80th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 154 | $143,619 |
| OzempicSemaglutide | 124 | $126,622 |
| JardianceEmpagliflozin | 107 | $105,402 |
| RybelsusSemaglutide | 59 | $77,785 |
| TrulicityDulaglutide | 44 | $43,465 |
| XareltoRivaroxaban | 30 | $26,787 |
| MounjaroTirzepatide | 18 | $24,757 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $16,431 |
| Bydureon BciseExenatide Microspheres | 13 | $11,134 |
| MyrbetriqMirabegron | 17 | $10,493 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 13 | $9,628 |
| Levothyroxine Sodium | 539 | $9,280 |
| Icosapent Ethyl | 34 | $8,266 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,604 |
| SynthroidLevothyroxine Sodium | 98 | $7,573 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $293 | $204,407183 claims |
| PfizerEliquis | $72 | $143,619154 claims |
| Boehringer IngelheimJardiance | $210 | $105,402107 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $69 | $68,22262 claims |
| Johnson & JohnsonXarelto | $143 | $26,78730 claims |
| GSKAnoro Ellipta, Breo Ellipta, Trelegy Ellipta | $119 | $23,22338 claims |
| Astellas Pharma US IncMyrbetriq | $84 | $10,49317 claims |
| AbbVieSynthroid | $282 | $7,57398 claims |
| AstraZenecaSymbicort | $251 | $4,41117 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Williamsville
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- David DoveEast Hampton$12.3M
- Robert CupeloEast Syracuse$10.6M
- Patrick ReaganRochester$9.4M
- Sally LauNew York$8.4M
- Angela BrancheRochester$7.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.